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A new challenge to public health has emerged in recent years from potent and untested 
drugs being sold under the guise of being ‘dietary’ supplements [1-4]. Fuelled by growing 
demand for products promising a better body, enhanced performance, and increased well-
being, this trend highlights creative marketing strategies used in the illicit supply of drugs.
Nine supplements suspected of containing drugs were analysed as part of investigation for 
the television programme Spotlight (Broadcasted 31 March 2015 by BBC Northern 
Ireland). The supplements were bought from high-street shops and from an e-commerce 
site (Table). Products were sold as ‘fat burners’ or ‘pro hormones’, with packaging often 
blatantly listing chemical names of drugs.
Ostarine belongs to the group of selective androgen receptor modulators (SARMs) and 
was found in Product 4. Ostarine is being tested as a medicine, but has not been 
authorised for marketing. The stimulant 1,3-dimethylamylamine (DMAA) was found in 
Product 1 and Product 2, and 1,3-dimethylbutylamine (DMBA) was found in Product 3 and 
Product 8. DMAA was recently identified in ‘dietary supplements’ and has been associated 
with adverse events, including acute myocardial infarction, strokes, and deaths [4]. Since 
regulators have removed DMAA from the market, an analogue DMBA has appeared as a 
replacement [3]. Products 6, 7, and 9 contained anabolic steroids, some of which have 
been associated with hepatoxicity [2]. Although advertised as legal ‘pro hormones’ they are 
controlled drugs in the UK.
1
These findings illustrate developments on the market, which now includes ‘dietary 
supplements’ containing medicines, ‘legal highs’, and controlled drugs. Many experienced 
users are aware of this marketing strategy. However, young or otherwise inexperienced 
people may be unknowingly exposing themselves to potent drugs. Clinicians should ask 
patients about the use of ‘supplements’ and report suspected adverse events to medicine 
agencies.
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Content of nine dietary supplements bought on the high-street and internet
Product No Label Content
1 Strip Tsa Caffeine, 
1,3-dimethylamylamine (DMAA), 
synephrine
2 Strip Tsa Caffeine, 
1,3-dimethylamylamine (DMAA), 
synephrine
3 Angel Dust Caffeine, 
1,3-dimethylbutylamine (DMBA)
4 Ostapure Ostarine 
5 Hemo Rage Caffeine, 
synephrine
6 SD Extreme Methasterone
7 Metha-Quad Extreme Methylstenbolone, 
methasterone, 
13-ethyl-3 methoxy-gona-2,5(10)-
dien-17-one.
8 Mutant Noxx Mass Power Blend Caffeine, 
1,3-dimethylbutylamine (DMBA)
9 M1T Hulk XT Methyl-1-testosterone
a Same product bought from two different shops.
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